Keeping Track: Breakthrough Therapies Becoming Breakthrough Applications For Tezacaftor, Burosumab, Emicizumab

The latest regulatory submission news and highlights from our US FDA Performance Tracker.

Keeping Track Feature image

Breakthrough therapy program continues to produce a steady flow of submissions. Products recently leaving the clinic for the FDA review arena include Vertex Pharmaceuticals Inc.'s latest cystic fibrosis therapy, a rare disease therapy from Ultragenyx Pharmaceutical Inc. and Kyowa Hakko Kirin Co. Ltd., and Roche's antibody for hemophilia A patients with inhibitors.

Kyowa Hakko Kirin had a particularly good week. The Japan-based company also announced a breakthrough therapy designation (BTD) for another...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from R&D

More from Pink Sheet